Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 ...
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...
In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 ROSELLA trial, which assessed the combination of relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian ...
The average age for an ovarian cancer diagnosis is after 63 ...
In this video, Ursula A. Matulonis, MD, shares insight on the phase 3 KEYNOTE-B96 trial of pembrolizumab combination therapy vs. placebo in patients with PD-L1-positive, platinum-resistant ovarian ...
MedPage Today on MSN
Advanced Ovarian Cancer Responds to Claudin-Targeted Drug in Preliminary Trial
Partial responses in half of patients with platinum-resistant disease, as crowded ADC list ...
Biomarkers in the blood could be used for the early detection of colorectal cancer, lung cancer and ovarian cancer. A new ...
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE)-- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical ...
Add Yahoo as a preferred source to see more of our stories on Google. Fabrice Coffrini/AFP via Getty Images (Fabrice Coffrini/AFP via Getty Images) Christiane Amanpour has been diagnosed with cancer ...
Dr. Premal Thaker reports IMNN-001 shows early survival benefit in ovarian cancer by activating immune response directly in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results